ALLK241220C500
- 0.75
- 0.000.00%
Allakos Newsroom
JMP Securities Maintains Allakos(ALLK.US) With Buy Rating, Maintains Target Price $3
Promising Potential of Allakos's AK006 Drives Buy Rating Amidst Market Interest in Chronic Spontaneous Urticaria
Allakos Reports Q3 2024 Results and Research Progress
Allakos Inc. Alters Lease Agreement for Cost Savings
All You Need to Know About Allakos (ALLK) Rating Upgrade to Buy
A Quick Look at Today's Ratings for Allakos(ALLK.US), With a Forecast Between $1 to $7
Cautious Hold Rating for Allakos Amid Uncertain Clinical and Financial Outlook
Piper Sandler Maintains Allakos(ALLK.US) With Buy Rating, Maintains Target Price $7
Barclays Maintains Allakos(ALLK.US) With Sell Rating, Maintains Target Price $1
Allakos GAAP EPS of -$0.21 Beats by $0.03
Allakos (ALLK) Gets a Hold From TD Cowen
Express News | Allakos Inc Q3 Shr View $-0.25 -- LSEG IBES Data
Express News | Allakos Inc: Reiterates That It Expects Restructuring Activities Will Extend Cash Runway Into Mid-2026
Allakos | 10-Q: Q3 2024 Earnings Report
Allakos | 8-K: Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results
Allakos 3Q Loss/Shr 21c >ALLK
Press Release: Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results
Express News | Allakos Q3 Net Income USD -18.372 Million
Express News | Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results
Express News | Allakos Q3 Operating Expenses USD 19.75 Million